ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Other Events
On March29, 2017, Anthera Pharmaceuticals, Inc. (the Company)
issued a press release announcing results from the extension
period of the Companys SOLUTION study of Sollpura.A copy of the
press release is filed herewith as Exhibit 99.1.
|Item9.01.||Financial Statements and Exhibits.|
|99.1||Press release dated March29, 2017|
About ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others. ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Recent Trading Information
ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) closed its last trading session up +0.010 at 0.440 with 7,528,735 shares trading hands.